Form 4: Prelude Therapeutics Executive Exercises Stock Options, Disposes of Shares for Tax Obligations

Jane Huang, President and CMO of Prelude Therapeutics, exercised stock options and disposed of shares to cover tax obligations on April 4, 2025.

Summary

• On April 4, 2025, Jane Huang, President and CMO of Prelude Therapeutics, exercised 9,375 Restricted Stock Units (RSUs), each representing one share of the company's common stock.
• Following the exercise, Huang disposed of 3,355 shares of common stock at a price of $0.675 to satisfy tax withholding obligations.
• After these transactions, Huang directly owns 74,877 shares of Prelude Therapeutics common stock and 37,500 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral report on routine stock transactions by an executive, with no indication of positive or negative sentiment.

Industry Context

This is a routine Form 4 filing, indicating insider transactions related to stock options and tax obligations, which is common for executives in publicly traded companies.

Stakeholder Impact

• The transactions have a minimal impact on shareholders, as they are related to routine executive compensation and tax obligations.

Key Dates

Keywords

Form 4, Prelude Therapeutics, PRLD, Jane Huang, Restricted Stock Units, RSU, Stock Options, Beneficial Ownership, Insider Trading